StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
80
This year
2
Publishing Date
2023 - 04 - 04
1
2023 - 03 - 23
1
2023 - 03 - 09
1
2023 - 03 - 02
1
2023 - 02 - 21
2
2023 - 01 - 10
1
2023 - 01 - 09
1
2022 - 12 - 23
1
2022 - 12 - 12
1
2022 - 11 - 23
1
2022 - 11 - 04
1
2022 - 10 - 25
1
2022 - 10 - 11
1
2022 - 09 - 30
1
2022 - 09 - 13
1
2022 - 09 - 08
1
2022 - 08 - 18
1
2022 - 08 - 17
1
2022 - 08 - 03
1
2022 - 08 - 01
2
2022 - 07 - 18
2
2022 - 07 - 14
1
2022 - 07 - 12
1
2022 - 06 - 24
1
2022 - 06 - 10
1
2022 - 05 - 30
1
2022 - 05 - 24
1
2022 - 05 - 20
1
2022 - 05 - 16
1
2022 - 05 - 11
1
2022 - 05 - 09
1
2022 - 04 - 29
1
2022 - 04 - 25
1
2022 - 04 - 11
1
2022 - 03 - 24
1
2022 - 03 - 14
1
2022 - 03 - 07
1
2022 - 03 - 03
1
2022 - 03 - 01
2
2022 - 02 - 28
1
2022 - 02 - 24
1
2022 - 02 - 18
1
2022 - 02 - 07
1
2022 - 02 - 02
1
2021 - 12 - 22
1
2021 - 12 - 14
2
2021 - 11 - 12
1
2021 - 11 - 05
1
2021 - 10 - 22
1
2021 - 09 - 29
1
2021 - 09 - 09
1
2021 - 08 - 30
1
2021 - 08 - 05
3
2021 - 07 - 29
1
2021 - 06 - 29
1
2021 - 05 - 24
2
2021 - 05 - 03
1
2021 - 04 - 26
1
2021 - 04 - 16
1
2021 - 03 - 19
1
Sector
Health technology
80
Tags
Acquisition
87
Alliances
89
America
64
Antibody
65
Approval
98
Biopharma
108
Biotech
87
Biotechnology
122
Business
82
Cancer
217
Children
68
Clinical-trials-phase-ii
51
Clinical-trials-phase-iii
80
Collaboration
102
Companies
59
Conference
58
Covid
128
Covid-19
111
Diabetes
60
Disease
179
Drug
244
Dupixent
118
Earnings
97
Europe
93
Events
61
Fda
237
Financial
164
Financial results
72
Genetown
74
Global
356
Growing
56
Growth
326
Health
71
Insulin
54
Iot
56
Market
720
Money
70
N/a
2823
News
129
People
224
Pharm-country
55
Pharma
193
Pharmaceutical
143
Positive
103
Potential
67
Regulatory
58
Report
312
Research
266
Results
368
Sanofi
202
Spac
62
Study
87
Technology
68
Therapeutics
344
Therapy
114
Treatment
281
Trial
166
Update
92
Vaccine
258
Year
61
Entities
Abbvie inc.
26
Abeona therapeutics inc.
4
Actinium pharmaceuticals, inc.
5
Aerie pharmaceuticals, inc.
4
Aldeyra therapeutics, inc.
12
Alnylam pharmaceuticals, inc.
14
Amgen inc.
9
Annovis bio, inc.
5
Apellis pharmaceuticals, inc.
5
Arcutis biotherapeutics, inc.
5
Ascendis pharma a/s
4
Astrazeneca plc
16
Bausch health companies inc.
4
Beigene, ltd.
11
Biofrontera inc.
4
Biogen inc.
4
Bristol-myers squibb company
20
Can-fite biopharma ltd
5
Cel-sci corporation
5
Clovis oncology, inc.
5
Concert pharmaceuticals, inc.
4
Deciphera pharmaceuticals, inc.
5
Edesa biotech, inc.
4
Eli lilly and company
32
Exelixis, inc.
15
Geron corporation
7
Gilead sciences, inc.
14
Glaxosmithkline plc
4
Greenwich lifesciences, inc.
7
Horizon therapeutics public limited company
11
Humanigen, inc.
7
Incyte corporation
12
Innoviva, inc.
4
Ionis pharmaceuticals, inc.
8
Johnson & johnson
52
Marinus pharmaceuticals, inc.
5
Mediwound ltd.
4
Merck & company, inc.
41
Moderna, inc.
6
Morphosys ag
4
Nektar therapeutics
5
Novartis ag
4
Novavax, inc.
4
Novocure limited
5
Ocugen, inc.
4
Oramed pharmaceuticals inc.
4
Orange
18
Pfizer, inc.
15
Regeneron pharmaceuticals, inc.
9
Sanofi
80
Scynexis, inc.
5
Seagen inc.
4
Seres therapeutics, inc.
6
Sierra oncology, inc.
5
Takeda pharmaceutical company limited
23
Teva pharmaceutical industries ltd
8
Therapeutic solutions international, inc.
7
Urogen pharma ltd.
5
Veru inc.
6
Vistagen therapeutics, inc.
5
Symbols
ALNY
6
AZN
2
DRRX
1
GLAXF
2
GSK
2
HGEN
1
INCY
3
IPHA
2
IPHYF
2
JNJ
7
LLY
4
NVO
2
REGN
6
SNY
80
SNYNF
67
TEVJF
4
VIR
1
Exchanges
Nasdaq
80
Nyse
13
Crawled Date
2023 - 03 - 23
1
2023 - 03 - 09
1
2023 - 03 - 02
1
2023 - 02 - 22
1
2023 - 02 - 21
1
2023 - 01 - 10
1
2023 - 01 - 09
1
2022 - 12 - 23
1
2022 - 12 - 12
1
2022 - 11 - 23
1
2022 - 11 - 04
1
2022 - 10 - 25
1
2022 - 10 - 11
1
2022 - 09 - 30
1
2022 - 09 - 13
1
2022 - 09 - 08
1
2022 - 08 - 18
1
2022 - 08 - 17
1
2022 - 08 - 03
1
2022 - 08 - 01
2
2022 - 07 - 18
2
2022 - 07 - 14
1
2022 - 07 - 12
1
2022 - 06 - 24
1
2022 - 06 - 10
1
2022 - 05 - 30
1
2022 - 05 - 24
1
2022 - 05 - 20
1
2022 - 05 - 16
1
2022 - 05 - 11
1
2022 - 05 - 09
1
2022 - 04 - 29
1
2022 - 04 - 25
1
2022 - 04 - 11
1
2022 - 03 - 24
1
2022 - 03 - 14
1
2022 - 03 - 07
1
2022 - 03 - 03
1
2022 - 03 - 01
2
2022 - 02 - 28
1
2022 - 02 - 24
1
2022 - 02 - 18
1
2022 - 02 - 07
1
2022 - 02 - 02
1
2021 - 12 - 22
1
2021 - 12 - 14
2
2021 - 11 - 12
1
2021 - 11 - 05
1
2021 - 10 - 22
1
2021 - 09 - 29
1
2021 - 09 - 09
1
2021 - 08 - 30
1
2021 - 08 - 05
3
2021 - 07 - 29
1
2021 - 06 - 29
1
2021 - 05 - 24
2
2021 - 05 - 03
1
2021 - 04 - 26
1
2021 - 04 - 16
1
2021 - 03 - 19
1
Crawled Time
00:00
1
05:00
1
06:00
1
07:00
1
08:00
1
09:00
4
10:00
1
11:00
3
12:00
4
12:20
2
12:30
2
13:00
8
13:20
1
13:30
1
14:00
5
14:15
1
14:20
2
14:30
2
15:00
5
15:20
4
15:30
3
16:00
10
17:00
6
18:00
4
19:00
2
20:00
1
21:00
2
22:00
1
23:00
1
Source
www.biospace.com
80
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Clinical-trials-phase-iii
entities :
Sanofi
save search
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published:
2024-03-25
(Crawled : 16:00)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
0.3%
|
O:
-100.0%
H:
NaN%
C:
Infinity%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-1.3%
|
O:
0.42%
H:
0.0%
C:
0.0%
fda
cancer
blood
therapy
Experts Take a ‘Wait and See’ Approach as BTK Inhibitors Stumble in MS
Published:
2024-01-29
(Crawled : 07:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-5.39%
|
O:
0.12%
H:
0.0%
C:
0.0%
Sanofi Axes Lung Cancer ADC After Phase III Trial Failure
Published:
2023-12-21
(Crawled : 18:00)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-1.99%
|
O:
-0.1%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-2.72%
|
O:
-0.08%
H:
0.0%
C:
0.0%
lung
axes
cancer
trial
sanofi
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published:
2023-11-27
(Crawled : 17:00)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-1.26%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
0.71%
|
O:
1.04%
H:
0.17%
C:
0.11%
dupixent
positive
copd
results
sanofi
Early October Sees Torrid Pace of Biotech M&A—Will It Continue?
Published:
2023-10-13
(Crawled : 21:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-13.6%
|
O:
-0.26%
H:
0.0%
C:
0.0%
biotech
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published:
2023-10-12
(Crawled : 15:30)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-14.67%
|
O:
-0.97%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-6.66%
|
O:
-1.87%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
24.27%
|
O:
0.54%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-13.48%
|
O:
0.14%
H:
0.0%
C:
0.0%
trial
Incyte’s Opzelura Clears Phase III Trial in Pediatric Atopic Dermatitis
Published:
2023-07-12
(Crawled : 15:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-8.57%
|
O:
-0.89%
H:
0.0%
C:
0.0%
opzelura
dermatitis
trial
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
Published:
2023-06-09
(Crawled : 15:20)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-6.61%
|
O:
2.58%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-7.95%
|
O:
-0.7%
H:
0.0%
C:
0.0%
crispr
Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
Published:
2023-05-12
(Crawled : 14:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-12.06%
|
O:
0.26%
H:
0.0%
C:
0.0%
report
rsv
Travere's Sparsentan Stumbles in Phase III Rare Kidney Disease Study
Published:
2023-05-03
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-11.15%
|
O:
0.71%
H:
0.0%
C:
0.0%
rare
disease
kidney
study
Sanofi Cleans House, Cuts Assets from Principia and Ablynx Buyouts
Published:
2023-04-27
(Crawled : 15:20)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-17.89%
|
O:
-3.56%
H:
0.0%
C:
0.0%
sanofi
Merck’s BTK Inhibitor Evobrutinib Slapped with Partial Clinical Hold
Published:
2023-04-13
(Crawled : 13:00)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-17.0%
|
O:
-1.1%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-15.16%
|
O:
0.29%
H:
0.0%
C:
0.0%
Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
Published:
2023-04-04
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-12.8%
|
O:
-0.1%
H:
0.0%
C:
0.0%
lancet
potential
Dupixent Clears Phase III in Bid to Become First Biologic for COPD
Published:
2023-03-23
(Crawled : 14:20)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-3.76%
|
O:
5.54%
H:
0.96%
C:
0.96%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-2.82%
|
O:
6.53%
H:
0.56%
C:
-0.54%
dupixent
copd
Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma
Published:
2023-03-09
(Crawled : 14:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-0.32%
|
O:
0.22%
H:
0.1%
C:
-1.36%
trials
therapeutics
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Published:
2023-03-02
(Crawled : 08:00)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
0.0%
|
O:
0.16%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
0.41%
|
O:
-0.76%
H:
1.58%
C:
1.58%
treatment
children
potential
study
Pfizer Gains on Astra and Sanofi in Infant RSV Prevention Race
Published:
2023-02-21
(Crawled : 00:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
0.19%
|
O:
0.79%
H:
0.0%
C:
0.0%
rsv
sanofi
Pfizer Gains on Astra and Sanofi in Maternal RSV Vaccine Race
Published:
2023-02-21
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
0.19%
|
O:
0.79%
H:
0.0%
C:
0.0%
vaccine
rsv
sanofi
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published:
2023-01-10
(Crawled : 19:00)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
115.02%
|
O:
-0.24%
H:
1.21%
C:
1.07%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-2.42%
|
O:
-0.49%
H:
0.0%
C:
0.0%
INCY
|
$51.74
0.17%
0.14%
1.6M
|
Health Technology
|
-34.36%
|
O:
0.1%
H:
2.05%
C:
0.82%
ibi362
chinese
diabetes
study
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
Published:
2023-01-09
(Crawled : 17:00)
- biospace.com/
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-1.88%
|
O:
1.38%
H:
0.28%
C:
0.28%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
107.25%
|
O:
0.29%
H:
0.27%
C:
-3.89%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-0.64%
|
O:
1.82%
H:
0.0%
C:
0.0%
INCY
|
$51.74
0.17%
0.14%
1.6M
|
Health Technology
|
-36.02%
|
O:
0.02%
H:
0.36%
C:
-2.56%
ibi362
chinese
diabetes
study
← Previous
1
2
3
4
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.